Diabetic nephropathy glomerular filtration rate (GFR) -
The eGFR is a marker used to evaluate renal function and to predict the risk for ESRD and renal death in diabetes cases, whereas the implication of creatinine-based eGFR is limited to hyperglycemia status.
Additionally, HbA 1c was positively associated with eGFR, whether independently or together with fasting plasma glucose FPG , in participants with prediabetes and was associated with significantly increased odds ratios ORs of hyperfiltration 21 , It was also demonstrated that eGFR equations were less accurate in the diabetic group than in the non-diabetic group, and HbA 1c was an independent factor associated with the accuracy of eGFR equations Several patients with T2D experienced eGFR FD or MD during the median 8-month follow-up.
From group FI to FD, baseline HbA 1c level, HbA 1c reduction range, and the age-adjusted prevalence of hyperfiltration increased gradually. Patients with FD had the highest baseline HbA 1c level, HbA 1c reduction, and a prevalence of hyperfiltration as high as This may be due to the HbA 1c reduction itself, but not as a result of hyperfiltration, since the association remained significant even after adjusting for the presence of hyperfiltration.
This was not the case at first sight. Existing research demonstrated HbA 1c reduction after a few months to be associated with a significant reduction in eGFR, and the correlation could be extended to both types of diabetes and more advanced stages of renal impairment.
In day-to-day clinical practice, the prediction of GFR becomes crucial when renal function declines. We note here that eGFR and its estimations would be significantly higher in poorly controlled patients.
There may be concerns about whether a decrease in eGFR indicates the decline of renal function, since the link between acute intensive glycemic control and acute neuropathies or DR progression is described in the literature 25 — The neuropathies experienced by patients were acute, severe but reversible, and did not occur as a consequence of chronic hyperglycemia.
The most important factors for the early worsening of DR were a higher HbA 1c level at screening and a reduction in this level during the first 6 months of treatment However, we cannot deny the long-term benefits of blood glucose control.
The retinal morphology improved during the following years, and intensive glycemic control continued to reduce DR progression 25 , 27 , A transient decrease in eGFR during the intervention period and its return to near the baseline level at weeks with SGLT-2i treatment indicated possible similar pathophysiological mechanisms and the development of a process for HbA 1c reduction 31 , A threshold for HbA 1c levels related to the risk of complications was observed.
Above the threshold of 6. The largest eGFR decline trend, along with HbA 1c reduction, was found in patients with hyperfiltration. The age-adjusted prevalence of hyperfiltration in this study was higher than that in a previous report The reason for this difference may have resulted from the different GFR measurement methods, definition criteria, study population, and HbA 1c levels 19 , It was found that a more considerable reduction in eGFR at 6 months significantly predicted a slower subsequent decline, and the amelioration of hyperfiltration was significantly associated with a slower long-term eGFR decline on follow-up Patients with hyperfiltration may benefit from an eGFR decline to the normal range.
Thus, caution is advised when interpreting eGFR before reaching adequate glycemic control and the amelioration of hyperfiltration, even in patients with long-term diabetes duration. Moreover, since eGFR equations were considered less accurate in patients with diabetes, regardless of using either the CKD-EPI or MDRD equations, eGFR changes and their response to treatment should be monitored better and regularly alongside HbA 1c.
This study identified the association between short-term changes in eGFR and HbA 1c in patients with T2D during the month follow-up period. Some patients with T2D experienced eGFR FD or MD during the median 8-month follow-up period. Since a downward trend in eGFR change was demonstrated alongside an HbA 1c reduction, regardless of the UACR stage and diabetes duration independent of hyperfiltration, sustained monitoring and the cautious interpretation of HbA 1c and eGFR changes are required in clinical practice.
We do not know whether the rapid eGFR decline associated with an HbA 1c reduction in this analysis will partly recover in future follow-ups, which requires further observation.
A weakness of this study concerns its retrospective nature. Thus, the study findings are hypothesis-generated and require further testing. The major strengths of the study were that it included a large study population and demonstrated an association between HbA 1c changes and short-term eGFR changes in populations with T2D; furthermore, all subjects were prospectively monitored using gold-standard procedures.
The results may thus present extensive external validity. Further inquiries can be directed to the corresponding author.
The studies involving human participants were reviewed and approved by the Ethics Committee of Beijing Ruijing Diabetes Hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.
LA and JL conceived and designed the study. LA analyzed the data and drafted the article. All authors contributed to data collection, critically reviewed the article, and approved the final version to be published.
This work was supported by the Beijing Fengtai District health system project No. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.
Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. We would like to express our gratitude to all those who helped us during the writing of this article.
Diabetes Atlas Group IDF. Update of Mortality Attributable to Diabetes for the IDF Diabetes Atlas: Estimates for the Year Diabetes Res ClinPract 3 —5. doi: CrossRef Full Text Google Scholar. Yu Y, Lin Q, Ye D, Wang Y, He B, Li Y, et al.
Neutrophil Count as a Reliable Marker for Diabetic Kidney Disease in Autoimmune Diabetes. BMC EndocrDisord 20 1 Jin D, Huang WJ, Meng X, Yang F, Bao Q, Zhang MZ, et al.
Chinese Herbal Medicine Tangshen Formula Treatment for Type 2 Diabetic Kidney Disease in the Early Stage: Study Protocol for a Randomized Controlled Trial. Trials 20 1 PubMed Abstract CrossRef Full Text Google Scholar.
Moon J, Lee CJ, Lee SH, Kang SM, Choi D, Yoo TH, et al. The Impact of Diabetes Mellitus on Vascular Biomarkers in Patients With End-Stage Renal Disease. Yonsei Med J 58 1 — American Diabetes Association.
Microvascular Complications and Foot Care: Standards of Medical Care in Diabetesd Diabetes Care 44 Suppl. The Microvascular Complications Group of Chinese Diabetes Association. Chinese Clinical Practice Guideline of Diabetic Kidney Disease.
Chin J Diabetes Mellitus 11 1 — Google Scholar. National Kidney Foundation. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
Chapter 1: Definition and classification of CKD. Kidney Intsuppl — National eGFR project cooperation group Collaboration. Modification and Evaluation of MDRD Estimating Equation for Chinese Patients With Chronic Kidney Disease.
Chin J Nephrol 22 10 — Espinel E, Agraz I, Ibernon M, Ramos N, Fort J, Serón D, et al. Low S, Zhang X, Wang J, Yeoh LY, Liu YL, Ang KKL, et al. Long-Term Prospective Observation Suggests That Glomerular Hyperfiltration Is Associated With Rapid Decline in Renal Filtration Function: A Multiethnic Study.
Diabetes Vasc Dis Res 15 5 — CrossRef Full Text Google Scholar. Premaratne E, Macisaac RJ, Tsalamandris C, Panagiotopoulos S, Smith T, Jerums G. Renal Hyperfiltration in Type 2 Diabetes: Effect of Age-Related Decline in Glomerular Filtration Rate. Diabetologia 48 12 — Pruijm M, Wuerzner G, Maillard M, Bovet P, Renaud C, Bochud M, et al.
Glomerular Hyperfiltration and Increased Proximal Sodium Reabsorption in Subjects With Type 2 Diabetes or Impaired Fasting Glucose in a Population of the African Region. Nephrol Dial Transplant 25 7 — Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, Carrara F, et al.
Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes. Diabetes Care 35 10 —8. Hong S, Choi YM, Ihm SH, Kim D, Choi MG, Yu JM, et al.
Association Between Metabolic Parameters and Glomerular Hyperfiltration in a Representative Korean Population Without Chronic Kidney Disease. PloS One 13 12 :e Zhao F, Zhang L, Lu J, Guo K, Wu M, Yu H, et al. The Chronic Kidney Disease Epidemiology Collaboration Equation Improves the Detection of Hyperfiltration in Chinese Diabetic Patients.
Int J Clin Exp Med 8 12 — Vidal-Petiot E, Courbebaisse M, Livrozet M, Corrégé G, Rusu T, Montravers F, et al.
Comparison of 51 Cr-Edta and 99m Tc-Dtpa for Glomerular Filtration Rate Measurement. J Nephrol 34 3 — Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ. The Clinical Significance of Hyperfiltration in Diabetes. Diabetologia 53 10 — Bjornstad P, Cherney DZ, Snell-Bergeon JK, Pyle L, Rewers M, Johnson RJ, et al.
Rapid Gfr Decline Is Associated With Renal Hyperfiltration and Impaired Gfr in Adults With Type 1 Diabetes.
Nephrol Dial Transplant 30 10 — Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular Hyperfiltration in Experimental Diabetes Mellitus: Potential Role of Tubular Reabsorption.
J Am Soc Nephrol 10 12 — Vallon V, Blantz RC, Thomson S. Glomerular Hyperfiltration and the Salt Paradox in Early [Corrected] Type 1 Diabetes Mellitus: A Tubulo-Centric View. J Am Soc Nephrol 14 2 —7. Thomson SC, Vallon V, Blantz RC. Kidney Function in Early Diabetes: The Tubular Hypothesis of Glomerular Filtration.
Am J Physiol Renal Physiol 1 :F8— Vallon V, Komers R. Pathophysiology of the Diabetic Kidney. Compr Physiol 1 3 — Vallon V, Thomson SC. Renal Function in Diabetic Disease Models: The Tubular System in the Pathophysiology of the Diabetic Kidney. Annu Rev Physiol — Takenaka T, Inoue T, Watanabe Y.
How the Kidney Hyperfiltrates in Diabetes: From Molecules to Hemodynamics. World J Diabetes 6 4 — The Tubular Hypothesis of Nephron Filtration and Diabetic Kidney Disease. Nat Rev Nephrol 16 6 — Thomson SC, Deng A, Bao D, Satriano J, Blantz RC, Vallon V.
Ornithine Decarboxylase, Kidney Size, and the Tubular Hypothesis of Glomerular Hyperfiltration in Experimental Diabetes. J Clin Invest 2 — Hallow KM, Gebremichael Y, Helmlinger G, Vallon V. Primary Proximal Tubule Hyperreabsorption and Impaired Tubular Transport Counterregulation Determine Glomerular Hyperfiltration in Diabetes: A Modeling Analysis.
Am J Physiol Renal Physiol 5 :F—F Provenzano M, Pelle MC, Zaffina I, Tassone B, Pujia R, Ricchio M, et al. Sodium—glucose Co-Transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge.
Front Med Lausanne Sasson AN, Cherney DZ. Renal Hyperfiltration Related to Diabetes Mellitus and Obesity in Human Disease. World J Diabetes 3 1 :1—6. Carmines PK. The Renal Vascular Response to Diabetes.
Curr Opin Nephrol Hypertens 19 1 — Kanai Y, Lee WS, You G, Brown D, Hediger MA. Delineation of the Major Renal Reabsorptive Mechanism for D-Glucose.
J Clin Invest 93 1 — Wright EM, Loo DD, Hirayama BA. Biology of Human Sodium Glucose Transporters. Physiol Rev 91 2 — Lang F, Gorlach A, Vallon V. Targeting Sgk1 in Diabetes. Expert Opin Ther Targets 13 11 — Freitas HS, Anhe GF, Melo KF, Okamoto MM, Oliveira-Souza M, Bordin S, et al.
Endocrinology 2 — Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM. Am J Physiol Cell Physiol 1 :C14— Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, et al.
Increase in Sglt1-Mediated Transport Explains Renal Glucose Reabsorption During Genetic and Pharmacological Sglt2 Inhibition in Euglycemia. Am J Physiol Renal Physiol 2 :F— Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, et al.
Knockout of Na-Glucose Transporter Sglt2 Attenuates Hyperglycemia and Glomerular Hyperfiltration But Not Kidney Growth or Injury in Diabetes Mellitus.
Powell DR, DaCosta CM, Gay J, Ding ZM, Smith M, Greer J, et al. Improved Glycemic Control in Mice Lacking Sglt1 and Sglt2.
Am J Physiol Endocrinol Metab 2 :E— Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, et al. Molecular Analysis of the Sglt2 Gene in Patients With Renal Glucosuria.
J Am Soc Nephrol 14 11 — Martín MG, Turk E, Lostao MP, Kerner C, Wright EM. Nat Genet 12 2 — Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, et al.
Sglt2 Mediates Glucose Reabsorption in the Early Proximal Tubule. J Am Soc Nephrol 22 1 — Diez-Sampedro A, Hirayama BA, Osswald C, Gorboulev V, Baumgarten K, Volk C, et al. A Glucose Sensor Hiding in a Family of Transporters.
Proc Natl Acad Sci USA 20 —8. Kothinti RK, Blodgett AB, North PE, Roman RJ, Tabatabai NM. A Novel Sglt Is Expressed in the Human Kidney. Eur J Pharmacol — Gyimesi G, Pujol-Gimenez J, Kanai Y, Hediger MA.
Sodium-Coupled Glucose Transport, the Slc5 Family, and Therapeutically Relevant Inhibitors: From Molecular Discovery to Clinical Application. Pflugers Arch 9 — Coady MJ, Wallendorff B, Gagnon DG, Lapointe JY.
J Biol Chem 38 — Tsai LJ, Hsiao SH, Tsai LM, Lin CY, Tsai JJ, Liou DM, et al. The Sodium-Dependent Glucose Cotransporter Slc5a11 as an Autoimmune Modifier Gene in Sle.
Tissue Antigens 71 2 — Gorboulev V, Schurmann A, Vallon V, Kipp H, Jaschke A, Klessen D, et al. Diabetes 61 1 — Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal Sodium—glucose Transport: Role in Diabetes Mellitus and Potential Clinical Implications.
Kidney Int 75 12 —7. Uehara-Watanabe N, Okuno-Ozeki N, Minamida A, Nakamura I, Nakata T, Nakai K, et al. Direct Evidence of Proximal Tubular Proliferation in Early Diabetic Nephropathy. Sci Rep 12 1 Vestri S, Okamoto MM, de Freitas HS, Aparecida Dos Santos R, Nunes MT, Morimatsu M, et al.
Changes in Sodium or Glucose Filtration Rate Modulate Expression of Glucose Transporters in Renal Proximal Tubular Cells of Rat. J Membr Biol 2 — Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose Transporters in Human Renal Proximal Tubular Cells Isolated From the Urine of Patients With Non-Insulin-Dependent Diabetes.
Diabetes 54 12 — Ackermann TF, Boini KM, Volkl H, Bhandaru M, Bareiss PM, Just L, et al. Sgk1-Sensitive Renal Tubular Glucose Reabsorption in Diabetes. Am J Physiol Renal Physiol 4 :F— Pontoglio M, Prié D, Cheret C, Doyen A, Leroy C, Froguel P, et al.
Hnf1alpha Controls Renal Glucose Reabsorption in Mouse and Man. EMBO Rep 1 4 — Chang J, Yan J, Li X, Liu N, Zheng R, Zhong Y. Update on the Mechanisms of Tubular Cell Injury in Diabetic Kidney Disease. Ravindran S, Munusamy S. Renoprotective Mechanisms of Sodium-Glucose Co-Transporter 2 Sglt2 Inhibitors Against the Progression of Diabetic Kidney Disease.
J Cell Physiol 2 — Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients With Chronic Kidney Disease. N Engl J Med 15 — Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al.
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 24 — Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes: Results From the Canvas Program Randomised Clinical Trials. Lancet Diabetes Endocrinol 6 9 — Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, et al.
Kidney Outcomes Associated With Use of Sglt2 Inhibitors in Real-World Clinical Practice Cvd-Real 3 : A Multinational Observational Cohort Study. Lancet Diabetes Endocrinol 8 1 — Dominguez Rieg JA, Rieg T. What Does Sodium-Glucose Co-Transporter 1 Inhibition Add: Prospects for Dual Inhibition.
Diabetes Obes Metab 21 Suppl — He Y, Pachori A, Chen P, Ma S, Mendonza AE, Amer A, et al. Glucosuric, Renal and Haemodynamic Effects of Licogliflozin, a Dual Inhibitor of Sodium-Glucose Co-Transporter-1 and Sodium-Glucose Co-Transporter-2, in Patients With Chronic Kidney Disease: A Randomized Trial.
Diabetes Obes Metab 23 5 — Moriya T, Tsuchiya A, Okizaki S, Hayashi A, Tanaka K, Shichiri M. Glomerular Hyperfiltration and Increased Glomerular Filtration Surface Are Associated With Renal Function Decline in Normo- and Microalbuminuric Type 2 Diabetes.
Kidney Int 81 5 — Wolf G, Ziyadeh FN. Molecular Mechanisms of Diabetic Renal Hypertrophy. Kidney Int 56 2 — Ohshiro Y, Ma RC, Yasuda Y, Hiraoka-Yamamoto J, Clermont AC, Isshiki K, et al. Reduction of Diabetes-Induced Oxidative Stress, Fibrotic Cytokine Expression, and Renal Dysfunction in Protein Kinase Cbeta-Null Mice.
Diabetes 55 11 — Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes.
Diabetes Care 28 11 — Koya D. Dual Protein Kinase C Alpha and Beta Inhibitors and Diabetic Kidney Disease: A Revisited Therapeutic Target for Future Clinical Trials. J Diabetes Investig 5 2 —8. Vallon V, Huang DY, Deng A, Richter K, Blantz RC, Thomson S.
Salt-Sensitivity of Proximal Reabsorption Alters Macula Densa Salt and Explains the Paradoxical Effect of Dietary Salt on Glomerular Filtration Rate in Diabetes Mellitus.
J Am Soc Nephrol 13 7 — Pedersen SB, Flyvbjerg A, Richelsen B. Inhibition of Renal Ornithine Decarboxylase Activity Prevents Kidney Hypertrophy in Experimental Diabetes.
Am J Physiol 2 Pt 1 :C—6. Miracle CM, Rieg T, Mansoury H, Vallon V, Thomson SC. Ornithine Decarboxylase Inhibitor Eliminates Hyperresponsiveness of the Early Diabetic Proximal Tubule to Dietary Salt. Am J Physiol Renal Physiol 4 :F—F Castrop H. Mediators of Tubuloglomerular Feedback Regulation of Glomerular Filtration: Atp and Adenosine.
Acta Physiol Oxf 1 :3— Thomson S, Bao D, Deng A, Vallon V. Sallstrom J, Carlsson PO, Fredholm BB, Larsson E, Persson AE, Palm F.
Diabetes-Induced Hyperfiltration in Adenosine a 1 -Receptor Deficient Mice Lacking the Tubuloglomerular Feedback Mechanism. Acta Physiol Oxf 3 —9. Faulhaber-Walter R, Chen L, Oppermann M, Kim SM, Huang Y, Hiramatsu N, et al. Lack of A1 Adenosine Receptors Augments Diabetic Hyperfiltration and Glomerular Injury.
J Am Soc Nephrol 19 4 — Brown R, Ollerstam A, Johansson B, Skøtt O, Gebre-Medhin S, Fredholm B, et al. Abolished Tubuloglomerular Feedback and Increased Plasma Renin in Adenosine A1 Receptor-Deficient Mice. Am J Physiol Regul Integr Comp Physiol 5 :R—7. Li L, Lai EY, Huang Y, Eisner C, Mizel D, Wilcox CS, et al.
Renal Afferent Arteriolar and Tubuloglomerular Feedback Reactivity in Mice With Conditional Deletions of Adenosine 1 Receptors. Am J Physiol Renal Physiol 8 :F— Vallon V, Schroth J, Satriano J, Blantz RC, Thomson SC, Rieg T. Adenosine a 1 Receptors Determine Glomerular Hyperfiltration and the Salt Paradox in Early Streptozotocin Diabetes Mellitus.
Nephron Physiol 3 :p30—8. Kidokoro K, Cherney DZI, Bozovic A, Nagasu H, Satoh M, Kanda E, et al. Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using in Vivo Imaging. Circulation 4 — Carlstrom M, Wilcox CS, Welch WJ. Adenosine A2a Receptor Activation Attenuates Tubuloglomerular Feedback Responses by Stimulation of Endothelial Nitric Oxide Synthase.
Persson P, Hansell P, Palm F. Adenosine A2 Receptor-Mediated Regulation of Renal Hemodynamics and Glomerular Filtration Rate Is Abolished in Diabetes.
Adv Exp Med Biol — Reduced Adenosine A2a Receptor-Mediated Efferent Arteriolar Vasodilation Contributes to Diabetes-Induced Glomerular Hyperfiltration.
Kidney Int 87 1 — Patinha D, Carvalho C, Abreu C, Cunha OM, Mota MC, Afonso J, et al. Learn how UpToDate can help you.
Select the option that best describes you. View Topic. Font Size Small Normal Large. Mechanisms of glomerular hyperfiltration in diabetes mellitus.
Formulary drug information for this topic. No drug references linked in this topic. Find in topic Formulary Print Share. View in. Language Chinese English.
Low GI side dishes kidneys filter your blood by removing waste nephtopathy Low GI side dishes water Dixbetic make Diqbetic. The glomerular Preventing diabetes-related digestive problems rate GFR shows how well raye kidneys are filtering. When found early, people can take important steps to protect their kidneys. Getting an accurate GFR level is challenging because measured GFR mGFR is a complicated and lengthy process. This makes it impractical for both clinicians and patients. It is for this reason that healthcare professionals use a formula to estimate GFR.Diabetic nephropathy glomerular filtration rate (GFR) -
Hyperfiltration is a typical feature of type 1 diabetic patients and type 2 diabetic patients. Although hyperglycemia is clearly involved in this hemodynamic abnormality, there is also increasing evidence that other factors such as obesity, insulin resistance and other metabolic factors associated with the metabolic syndrome may contribute both to hyperfiltration and nephromegaly.
Several clinical studies suggested a possible role of hyperfiltration as a causative factor in renal disease progression, although ad hoc studies are needed to assess whether glomerular hyperfiltration can be a specific target for renoprotective intervention.
Therapy with SGLT-2 inhibitors may correct hyperfiltration in diabetes and a recent clinical trial showed that they may contribute to reduce the progression of renal disease in type 2 diabetic patients.
declares no potential conflicts of interest relevant to this article. Contribution from the CME course of the DIABESITY Working Group of the ERA-EDTA, Bergamo, December , Sign In or Create an Account. Search Dropdown Menu.
header search search input Search input auto suggest. filter your search All Content All Journals Nephron. Advanced Search. Skip Nav Destination Close navigation menu Article navigation. Volume , Issue 4. Hyperfiltration, a Typical Feature of Diabetes in Humans.
Hyperfiltration: Definition and Mechanisms. Hyperfiltration in Type 2 Diabetic Patients: Relation with Renal Disease Progression. Hyperfiltration: A Possible Therapeutic Role for SGLT-2 Inhibitors. Disclosure Statement. Article Navigation. Review Articles December 16 The Hyperfiltering Kidney in Diabetes Topic Article Package: Topic Article Package: Diabetes.
Subject Area: Nephrology. Roberto Trevisan ; Roberto Trevisan. USC Malattie Endocrine - Diabetologia, ASST Papa Giovanni XXIII, Bergamo, Italy. rtrevisan fastwebnet.
This Site. Google Scholar. Alessandro Roberto Dodesini Alessandro Roberto Dodesini. Nephron 4 : — Article history Received:. Cite Icon Cite. toolbar search Search Dropdown Menu. toolbar search search input Search input auto suggest. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.
J Clin Invest ; Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG: Is hyperfiltration associated with the future risk of developing diabetic nephropathy?
A meta-analysis. Diabetologia ; Ficociello LH, Perkins BA, Roshan B, Weinberg JM, Aschengrau A, Warram JH, Krolewski AS: Renal hyperfiltration and the development of microalbuminuria in type 1 diabetes.
Diabetes Care ; Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ: The clinical significance of hyperfiltration in diabetes.
Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, Carrara F, Cella C, Ferrari S, Stucchi N, Parvanova A, Iliev I, Dodesini AR, Trevisan R, Bossi A, Zaletel J, Remuzzi G; GFR Study Investigators: Glomerular hyperfiltration and renal disease progression in type 2 diabetes.
Mogensen CE: Glomerular hyperfiltration in human diabetes. Wiseman MJ, Saunders AJ, Keen H, Viberti G: Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes.
N Engl J Med ; Hansen KW, Mau Pedersen M, Christensen CK, Schmitz A, Christiansen JS, Mogensen CE: Normoalbuminuria ensures no reduction of renal function in type 1 insulin-dependent diabetic patients. J Intern Med ; Persson P, Hansell P, Palm F: Tubular reabsorption and diabetes-induced glomerular hyperfiltration.
Acta Physiol Oxf ; Vallon V, Richter K, Blantz RC, Thomson S, Osswald H: Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption.
Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Menne J, Ritz E, Ruilope LM, Chatzikyrkou C, Viberti G, Haller H. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention ROADMAP observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.
J Am Heart Assoc. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials [published correction appears in BMJ.
Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [published correction appears in N Engl JMed. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemo-dialysis [published correction appears in N Engl J Med.
Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Lifestyle management: standards of medical care in diabetes— TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial [published correction appears in Diabetes Care.
Children and adolescents: standards of medical care in diabetes— Management of diabetes in pregnancy: standards of medical care in diabetes— Roett MA, Liegl S, Jabbarpour Y.
Diabetic nephropathy—the family physician's role. Am Fam Physician. This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.
search close. PREV Jun 15, NEXT. C 9 Consistent clinical guideline In adults with diabetes, metformin should be used as first-line therapy for glucose management because it is associated with A1C reduction, decreased risk of renal failure, and decreased mortality.
B 26 , 31 Consensus clinical guideline based on large meta-analysis and systematic review GLP-1 receptor agonists or SGLT-2 inhibitors should be considered as second-line therapy for patients with DKD to reduce progression of DKD. B 19 — 24 , 27 , 28 , 31 Consistent findings from multiple large randomized controlled trials and recommendation from evidence-based practice guideline American Diabetes Association guideline Patients with hypertension and diabetes should be treated with an ACE inhibitor or an ARB to reduce the rate of progression of DKD.
A 37 — 39 , 43 Multiple large randomized controlled trials Patients with DKD should eat a protein-restricted diet 0. C 48 , 49 Large meta-analysis For women of reproductive age with diabetes, ACE inhibitor or ARB therapy should be initiated only after discussion of potentially teratogenic effects.
C 51 Expert-based clinical guideline. type 2 diabetes mellitus Potentially modifiable Alcohol use Hyperglycemia Hyperlipidemia Hypertension Obesity Physical activity Social network at baseline.
Screening and Diagnosis. GLYCEMIC CONTROL. BLOOD PRESSURE CONTROL. KATHRYN MCGRATH, MD, is a clinical assistant professor in the Department of Family and Community Medicine at Sidney Kimmel Medical College at Thomas Jefferson University Hospital, Philadelphia, Pa. mcgrath jefferson.
Thorp ML. Diabetic nephropathy: common questions. Continue Reading. More in AFP. More in Pubmed. Copyright © by the American Academy of Family Physicians. Copyright © American Academy of Family Physicians.
All Rights Reserved. Individuals with type 2 diabetes mellitus should be screened for albuminuria at the time of diagnosis and annually thereafter. In adults with diabetes, metformin should be used as first-line therapy for glucose management because it is associated with A1C reduction, decreased risk of renal failure, and decreased mortality.
Consensus clinical guideline based on large meta-analysis and systematic review. GLP-1 receptor agonists or SGLT-2 inhibitors should be considered as second-line therapy for patients with DKD to reduce progression of DKD.
Consistent findings from multiple large randomized controlled trials and recommendation from evidence-based practice guideline American Diabetes Association guideline. Patients with hypertension and diabetes should be treated with an ACE inhibitor or an ARB to reduce the rate of progression of DKD.
Patients with DKD should eat a protein-restricted diet 0. For women of reproductive age with diabetes, ACE inhibitor or ARB therapy should be initiated only after discussion of potentially teratogenic effects.
Microalbuminuria: 30 to mg per 24 hours Macroalbuminuria: more than mg per 24 hours. Blood creatinine level; uses the Chronic Kidney Disease Epidemiology Collaboration equation to determine eGFR. Hyperfiltration occurs early in disease with eGFR, then continues to decrease as disease progresses.
Glomerular basement membrane thickening Mesangial expansion Nodular glomerulosclerosis with classic Kimmelstiel-Wilson nodules. Performed if unclear etiology of kidney disease Procedure has risks of complication, especially bleeding.
Microalbuminuria: 30 to mg per g Macroalbuminuria: more than mg per g. Timed 4-hour or over-night urine collection mcg of albumin per minute. Microalbuminuria: 20 to mcg Macroalbuminuria: more than mcg. Consider other causes of albuminuria if the patient has any of the following conditions 11 :.
Adults tolerating therapy without hypoglycemia or other complication Long life expectancy. Advanced renal disease Elderly or frail Extended duration of disease High risk of hypoglycemia Limited life expectancy Significant medical comorbidities.
Dipeptidyl-peptidase-4 inhibitors 19 — Increase and prolong incretin activity, thus increasing insulin release from pancreatic beta cells; reduce glucagon secretion Decrease albuminuria independent of effects on glucose and blood pressure Synergistic with telmisartan Micardis.
Increase risk of hypoglycemia when used in combination with insulin or sulfonylureas Not studied for patients with type 1 diabetes mellitus Caution in patients with known heart failure.
Glucagon-like peptide-1 receptor agonists 22 — Increase insulin secretion by pancreatic beta cells in presence of hyperglycemia; delay gastric emptying Reduce renal oxidative stress Protect renal endothelial cells Suppress renal inflammatory cytokines. LEADER trial showed decreased rate of DKD as secondary outcome decreased proteinuria; no effect on advanced disease outcomes 22 SUSTAIN-6 trial showed decreased rate of progression to macroalbuminuria 24 Trials showed fewer cardiac events; lower all-cause mortality.
Adverse effects: mostly gastrointestinal; associated with increased risk of pancreatitis and acute gallbladder disease May not prevent progression of retinopathy FDA boxed warning: contraindicated in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Improves insulin sensitivity First-line agent for patients with type 2 diabetes No risk for hypoglycemia Can safely be used in patients with type 1 diabetes. Improves glucose control Long-term use impairs vitamin B 12 absorption The U. Diabetes Res ClinPract 3 —5.
doi: CrossRef Full Text Google Scholar. Yu Y, Lin Q, Ye D, Wang Y, He B, Li Y, et al. Neutrophil Count as a Reliable Marker for Diabetic Kidney Disease in Autoimmune Diabetes. BMC EndocrDisord 20 1 Jin D, Huang WJ, Meng X, Yang F, Bao Q, Zhang MZ, et al. Chinese Herbal Medicine Tangshen Formula Treatment for Type 2 Diabetic Kidney Disease in the Early Stage: Study Protocol for a Randomized Controlled Trial.
Trials 20 1 PubMed Abstract CrossRef Full Text Google Scholar. Moon J, Lee CJ, Lee SH, Kang SM, Choi D, Yoo TH, et al. The Impact of Diabetes Mellitus on Vascular Biomarkers in Patients With End-Stage Renal Disease. Yonsei Med J 58 1 — American Diabetes Association. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetesd Diabetes Care 44 Suppl.
The Microvascular Complications Group of Chinese Diabetes Association. Chinese Clinical Practice Guideline of Diabetic Kidney Disease. Chin J Diabetes Mellitus 11 1 — Google Scholar. National Kidney Foundation. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
Chapter 1: Definition and classification of CKD. Kidney Intsuppl — National eGFR project cooperation group Collaboration. Modification and Evaluation of MDRD Estimating Equation for Chinese Patients With Chronic Kidney Disease.
Chin J Nephrol 22 10 — Espinel E, Agraz I, Ibernon M, Ramos N, Fort J, Serón D, et al. Renal Biopsy in Type 2 Diabetic Patients. J Clin Med — Krolewski AS, Skupien J, Rossing P, Warram JH. Fast Renal Decline to End-Stage Renal Disease: An Unrecognized Feature of Nephropathy in Diabetes.
Kidney Int 91 6 — Skupien J, Warram JH, Smiles AM, Niewczas MA, Gohda T, Pezzolesi MG, et al. The Early Decline in Renal Function in Patients With Type 1 Diabetes and Proteinuria Predicts the Risk of End-Stage Renal Disease. Kidney Int 82 5 — Xie D, Shi H, Xie J, Ding Y, Zhang W, Ni L, et al.
A Validation Study on eGFR Equations in Chinese Patients With Diabetic or Non-Diabetic CKD. Front Endocrinol Lausanne Hsu CC, Kao WL, Steffes MW, Gambir T, Brancati FL, Heilig CW, et al. Genetic Variation of Glucose Transporter-1 GLUT1 and Albuminuria in 10, European Americans and African Americans: A Case-Control Study in the Atherosclerosis Risk in Communities ARIC Study.
BMC Med Genet Rigalleau V, Lasseur C, Raffaitin C, Perlemoine C, Barthe N, Chauveau P, et al. Glucose Control Influences Glomerular Filtration Rate and its Prediction in Diabetic Subjects. Diabetes Care 29 7 —5. Preventive group of Chinese Society of Cardiology. Chinese Expert Consensus on the Management of Elevated Triglycerides in Patients With Atherosclerosis.
Chin J Gen Pract 17 5 — Chinese Guideline for Prevention and Treatment of Type 2 Diabetes Edition. Chin J Diabetes Mellitus 10 1 :4— Levey AS, Coresh J, Balk E, Kausz AT, Levin T, Steffes MW, et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification.
Ann Intern Med — Zhang J, Wei J, Jiang S, Xu L, Wang L, Cheng F, et al. Macula Densa SGLT1-NOS1-Tubuloglomerular Feedback Pathway, a New Mechanism for Glomerular Hyperfiltration During Hyperglycemia.
J Am SocNephrol 30 4 — Ruggenenti P, Porrini EL, Gaspari F, Trevisan R, Bossi A, Zaletel J, et al. GFR Study Investigators. Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes.
Diabetes Care 35 10 —8. Wiseman MJ, Saunders AJ, Keen H, Viberti G. Effect of Blood Glucose Control on Increased Glomerular Filtration Rate and Kidney Size in Insulin-Dependent Diabetes.
N Engl J Med 10 — Rodríguez-Poncelas A, Franch-Nadal J, Coll-de Tuero G, Mata-Cases M, Alonso-Fernández M, Mur-Marti T, et al.
High Levels of Fasting Glucose and Glycosylated Hemoglobin Values are Associated With Hyperfiltration in a Spanish Prediabetes Cohort.
The PREDAPS Study. PloS One 14 9 :e Rodriguez-Poncelas A, Coll-de-Tuero G, Blanch J, Comas-Cufí M, Saez M, Barceló MA, et al. Prediabetes Is Associated With Glomerular Hyperfiltration in a European Mediterranean Cohort Study. J Nephrol 31 5 —9. Sun ZJ, Yang YC, Wu JS, Wang MC, Chang CJ, Lu FH, et al.
Increased Risk of Glomerular Hyperfiltration in Subjects With Impaired Glucose Tolerance and Newly Diagnosed Diabetes.
Nephrol Dial Transplant 31 8 — Hou X, Wang C, Wang S, Yang W, Ma Z, Wang Y, et al. PloS One 9 10 :e
BMC Low GI side dishes Diabetlc Low GI side dishes glomerrular, Article number: nephropathh Cite this article. Metrics details. Type 2 diabetes nephropathy T2DN. There has been a paucity of data focused on the rate of transition of T2 DN. Based on our personal observation a certain percentage of our incident end stage renal disease ESRD patients from T2DN experienced a rapid decline of renal function. All the patients are heavily nephrotic.
We include products we think are Ne;hropathy for Pre-game meal ideas for team sports readers. If you buy Diabetic nephropathy glomerular filtration rate (GFR) links on this page, we may earn a small commission. Healthline filtratikn shows you brands and products that we stand behind. A GFR of over 90 is considered normal. But having a GFR of 60 or above may also considered within the normal range if you do not have other signs of kidney disease. Diabetes is a long-term chronic health condition where your blood sugar is too high. 
Bitte, erzählen Sie ausführlicher.
Geben Sie wir werden zu diesem Thema reden.
Sie sind nicht recht. Geben Sie wir werden es besprechen. Schreiben Sie mir in PM, wir werden umgehen.